drugset / Trial / NCT03519113
HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a clinical study for GC1102 to demonstrate preventing the recurrence of hepatitis B virus (HBV) infection following liver transplantation and a dose-finding study to determine its optional dose.
Timeline
- Start
- 2018-03-29
- Primary completion
- 2022-03-31
- Completion
- 2022-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LENVERVIMAB | Monoclonal antibody | 80000 iu | Intravenous |
| Subject | LENVERVIMAB | Monoclonal antibody | 100000 iu | Intravenous |
| Comparator | hepatitis B immune globulin | Protein / enzyme biologic | — | Intravenous |